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Abstract: Despite tremendous progress made during the last few decades in the treatment options
for cancer, compounds isolated from Mother Nature remain the mainstay for therapy of various
malignancies. Fangchinoline, initially isolated from the dried root of Stephaniae tetrandrine, has been
found to exhibit diverse pharmacological effects including significant anticancer activities both in
tumor cell lines and selected preclinical models. This alkaloid appears to act by modulating the
activation of various important oncogenic molecules involved in tumorigenesis leading to a significant
decrease in aberrant proliferation, survival and metastasis of tumor cells. This mini-review briefly
describes the potential effects of fangchinoline on important hallmarks of cancer and highlights the
molecular targets modulated by this alkaloid in various tumor cell lines and preclinical models.
Keywords: fangchinoline; cancer; apoptosis; proliferation; molecular targets
1. Introduction
On a global scale, cancer is considered as the second major disease that causes significant
morbidity, making it a major public health concern. Indeed, despite a positive response to initial
treatment options, a number of patients may develop local recurrence and propagation of the primary
tumor [1]. Cancer may arise as a consequence of genetic dysfunction, amplification, mutations,
repression, and deletion of genes [2]. It involves multiple steps such as initiation: Mutations by
alteration of the DNA under the influence of carcinogens; promotion: Clonal expansion with formation
of a tumor; proliferation: With two often simultaneous steps of spreading of malignant cells in
the nearby organs and metastasis and dissemination of cancer cells [3]. In addition, an increase in
proliferation combined with a decrease in apoptosis favors an increase in number of actively dividing
tumor cells, thereby leading to in situ cancer [4]. Therefore, the design and development of novel
agents derived from natural sources that are known to affect multiple molecular and cellular targets is
being explored as an effective approach for cancer treatment [5,6].
Natural products and bioactives refer to compounds, exclusive of essential nutrients, that have a
biological activity in humans [7–9]. They have been historically a mainstay source of anti-cancer drugs.
It has been demonstrated that drugs derived from natural compounds may be more effective for cancer
treatment than those produced synthetically [10]. Currently, it is known that approximately 10,000
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out of 500,000 plant species potentially contain medicinal substances [11]. According to the United
States Food and Drug Administration (US FDA), natural products and their derivatives represent
one-third of all novel drugs. For cancer therapy, almost 80% of all drugs approved by the US FDA
during the last three decades are natural products, their derivatives, or drugs designed based upon a
natural product structure. New technologies and analysis methods, such as combinatorial synthesis
and high-throughput screening, have brought a fresh perspective for the discovery and the design of
novel compounds from natural sources, including medicinal plants [1,12–15].
A summary of the drugs derived from natural products and then used as active ingredients for
anti-tumor drugs approved by the FDA is now provided. Irinotecan, a chemotherapy drug used to
treat colorectal cancer, extracted from Camptotheca acuminata was approved by the FDA in 1996 [16].
Etoposide, an epipodophyllotoxin, is a chemotherapeutic drug used for the treatment of various human
cancers including small cell lung and testicular cancers. It is extracted from Podophyllum peltatum
and was approved by the FDA in 1983 [17,18]. Masoprocol is used to treat actinic keratoses and was
originally extracted from Larrea tridentata and was approved by the FDA in 1992 [19]. Teniposide, which
is extracted from podophyllum, is used to cure acute lymphocytic leukemia through the inhibition
of DNA synthesis by the formation of a complex with topoisomerase II and DNA, which leads to
DNA breaks. The accumulation of the DNA fragments can prevent cells from entering the mitotic
phase during the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases
of the cell cycle, and its use was approved by the FDA in 1992 [20]. Paclitaxel, which is derived
from Taxus brevifolia, can induce the polymerization of microtubules thus causing apoptosis and was
approved for clinical use by the FDA in 1992 [21]. Docetaxel, a semi-synthetic taxane can also bind to
tubulin, thus stabilizing microtubules and inducing apoptosis. Its use was approved by the FDA in
1996 [22]. Finally, vinorelbine, a vinca alkaloid derived from Catharanthus roseus, was approved as a
medicine for non-small cell lung cancer by the FDA in 1994 [23].
2. Fangchinoline Classification
Fangchinoline is a traditional chinese medicine isolated from the dried root of Stephaniae tetrandrine
S. Moore (family-menispermaceae) [24]. This bisbenzylisoquinoline alkaloid (Figure 1) showed
significant anti-cancer effects in several tumor cell lines, including MDA-MB-231 breast cancer
cells [25–27], MG63 and U20S bone cancer cell lines [28], A549 lung cancer cell lines [29], PC3 human
prostate cancer cell lines [30], K562 myelogenous leukemia cells [31], T24 and 5637 bladder cancer cell
lines [32], human gastric cancer cells AGS [33], and U87 MG and U118 MG glioblastoma multiforme
cancer cell lines [34].
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3. Fangchinoline-Reported Anti-Cancer Effects in Vitro and in Vivo
3.1. Effect on Tumor Cell Proliferation
Proliferation is an important part of tumor development and progression. To multiply,
cancer cells short-circuit a number of the regulatory pathways involved in proliferation, allowing
them to grow in an uncontrolled manner. These cells have several approaches to avoid cellular
senescence [35], which is a phenomenon that allows the limiting of the replicative capacity of
cells, thus preventing their proliferation at different stages of malignancy. Fangchinoline has
been reported to exhibit potent anti-proliferation effects against several types of tumor cells.
Its anti-proliferative activity and effect on various regulators of cell growth has been substantiated
in a variety of malignant cells, including bone cancer/osteosarcoma (MG63 and U20S) [28], breast
cancer (MDA-MB-231) [25,27], and lung adenocarcinoma (SPC-A-1) [36] by various methods such as
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide (MTT) assay, flow cytometric analysis,
Western blot, and reverse transcription polymerase chain reaction (RT-PCR) techniques.
Osteosarcoma (also called osteogenic sarcoma) is the most common bone cancer, and it affects
mostly children and young adults [37]. Preoperative chemotherapy is the current treatment option,
but it has a limited long-term effect to prevent the progression of disease. Fangchinoline was
found to significantly decrease the proliferation of MG63 and U20S bone cancer cell lines, along
with the suppression of migration of MG63 cells [28]. In MDA-MB-231 as well as SPC-A-1
cells, a time-dependent significant inhibition of cell proliferation has been shown following
treatment with fangchinoline [25,36]. A study by Guo et al., on A549 lung adenocarcinoma
cell line treated with fangchinoline, revealed the potential of the drug to cause suppression of
both proliferation and invasion [29]. In T24 and 5637 bladder cancer cell lines treated with
fangchinoline, a concentration-dependent reduction of intracellular ATP levels were associated
with a down-regulation of cell proliferation [32]. Additionally, it was found that treatment of
the PC3 human prostate cancer cell line with fangchinoline resulted in the attenuation of cell
proliferation [30]. Furthermore, fangchinoline can induce a substantial inhibition of cell proliferation
in K562 myelogenous leukemia cells derived from the blast crisis of chronic myeloid leukemia [31].
3.2. Anti-Metastatic Effects
Metastasis is the leading reason for the resultant mortality of patients with cancer. It represents
the end-product of the invasion and metastasis cascade, and involves the dissemination of tumor cells
to distant organs followed by their adaptation to the new tissue microenvironments [38]. Melanoma
is a tumor with a high degree of malignancy, metastasis, and mortality. The etiology of melanoma
has not been fully elucidated, and there is no effective drug for its complete treatment [39]. In a
recent study conducted on A375 and A875 melanoma cell lines, it has been shown that fangchinoline
could significantly inhibit cell metastasis and migration (IC50 values of 12.41 and 16.20 µM) in a
concentration-dependent manner [40] as determined by scratch wound healing and transwell assays.
A glioma is a tumor that starts in the glial cells of the brain or the spine [41]. It can be classified
clinically following the grade of the tumor in four grades, from grade I to grade IV, depending on the
growth rate [42–45]. Among various glial tumors, glioblastoma multiforme (GBM, a grade IV glioma)
is the most aggressive but also sadly the most common and destructive cancer that occurs in human
brains. Indeed, most patients with GBMs have a life expectancy of less than one year, with a short-term
survival. Over the last fifty years, GBMs have evaded increasingly clever and intricate attempts at
therapy [46]. It has been shown that fangchinoline inhibits tumor cell invasiveness and proliferation
in U87 MG and U118 MG GBM cell lines [34]. In AGS human gastric cancer cells, fangchinoline, in a
dose-dependent manner, suppressed the adhesion, migration, and invasion of the cells without any
obvious cytotoxic effects [33].
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3.3. Effects on Apoptosis and Autophagy
Apoptosis, also known as the process of programmed cell death, is highly selective; and thus
in both physiological and pathological conditions, apoptosis is generally characterized by specific
morphological characteristics that concern both the nucleus and the cytoplasm, in which three principal
changes at the biochemical level can be observed: Expression of phosphatidylserine (PS) in the outer
layer membrane, followed by its recognition by phagocytes, and finally activation of caspases. Defects
in apoptosis can cause cancer or autoimmune diseases, while enhanced apoptosis may also lead to
various degenerative diseases [4,47–49].
Autophagy is an intracellular catabolic degradative process, which allows capturing and
degradation of intracellular components (proteins, organelles) to sustain homeostasis and
metabolism [50]. Over time, one can observe cellular toxicity if there is an accumulation of damaged
proteins and organelles in the cells, which is why low levels of basal autophagy play an important
role in protein and organelle turnover [51,52]. In cancer, autophagy may have two opposite roles:
It can function as a tumor suppressor or as a tumor promoter. This can be explained by the fact that
autophagy can be either cytoprotective or cytotoxic through mechanisms that are still not completely
clarified [53,54].
Fangchinoline has been shown to induce apoptosis in diverse malignant cells by various
techniques (such as Hoechst 33258 staining, Annexin V-fluorescein isothiocyanate or Annexin
V-propidium iodide methods) including human U118 and U87 MG grade IV GBM cell lines [34].
Additionally, increased exposure time to fangchinoline caused an up-regulation of apoptosis in PC3
prostate cells [30]. T24 and 5637 bladder cancer cell lines treated with fangchinoline demonstrated
increased apoptosis and adaptive autophagy in a concentration-dependent manner [32]. It was
found that, in human pancreatic cancer cells, fangchinoline induced apoptosis [55]. Fangchinoline
significantly decreased MDA-MB-231 breast tumor cell growth and induced apoptosis in a
concentration-dependent manner [56]. In the human liver cancer cell lines PLC/PRF/5 and HepG2,
fangchinoline induced autophagy in an irreversible way [57]. Fangchinoline was also found to
significantly increase apoptosis in MG63 and U20S bone cancer cell lines [28].
3.4. Molecular Targets
Fangchinoline has been observed to exert growth modulatory, pro-apoptotic/autophagic
and anti-metastatic effects, as described in the above sections, by modulating a wide variety of
different cellular signal transduction cascades. These effects of fangchinoline on a few important
molecular targets are briefly discussed in this section. Previous studies have demonstrated that
the regulation of cellular growth predominantly depends on a number of tumor suppressors,
protooncogenes/oncogenes, and also signaling molecules, such as phosphatidylinositol-3-kinase
(PI3K) and protein kinase B (Akt) [58]. PI3K is a lipid kinase that can be activated by receptor tyrosine
kinases, leading to an important secondary messenger phosphatidylinositol-3,4,5-trisphosphate
production, thus allowing protein kinase B (PKB) to be activated by its translocation to the plasma
membrane. PKB (also known as Akt), is a serine/threonine protein kinase [59]. Its phosphorylation by
phosphoinositide-dependent kinase (PDK) 1 and 2 of two of its residues (threonine 308 (Thr308)
in the activation loop and serine 473 (Ser473) in the C-terminal hydrophobic motif) induces
its activation [60,61]. PKB plays a key regulatory role in cell survival and proliferation [62].
This role includes the inactivation of pro-survival factors, including glycogen synthase kinase-3-beta
(GSK-3β) [63]. In addition, it has been demonstrated that PKB phosphorylates the cell cycle inhibitory
protein p21(Cip1) at Thr 145, which inhibits DNA replication [64], as well as Bcl-2-associated death
promoter (BAD), a member of the BCL-2 family, thus permitting the promotion of cellular survival [65].
It has been shown that PI3K-Akt activation is required for the induction of membrane type 1
metalloproteinase (MT1-MMP) [66,67], a transmembrane MMP that plays a major role in extracellular
matrix remodeling; directly by degrading several of its components and indirectly by activating
pro-MMP2, an ubiquitinous MMP that is involved in diverse functions such as angiogenesis and tumor
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invasion, as well as degradation of extracellular matrix proteins [68]. MT1-MMP can also up-regulate
the expression of vascular endothelial growth factor expression and thus promote tumor growth and
angiogenesis [69].
Extracellular matrix interactions with cells play a critical role in tumor metastasis [70]. Focal
adhesion kinase (FAK) is an ubiquitous cytoplasmic tyrosine kinase known as a key mediator of
signaling by integrins, which are the principal receptors on animal cells for binding most extracellular
matrix proteins including laminins, growth factors, collagens, and fibronectin [71,72]. MMP-9, which is
involved in the degradation of the extracellular matrix, plays an important role in tumor invasion and
metastasis, and its expression is regulated by various growth factors, including TGF-β1, in different
cell types [73]. In integrin-mediated cell adhesion, FAK is activated through the disruption of an
auto-inhibitory intra-molecular interaction between its amino terminal FERM (F for 4.1 protein, E for
ezrin, R for radixin and M for moesin) domain and the central kinase domain. The activated FAK
forms a complex with Src family kinases, initiating multiple downstream signaling pathways through
phosphorylation of other proteins to regulate different cellular functions including metastasis [71].
It has been shown that FAK is over-expressed in several cancer cell lines, including human colorectal
cancer [74,75]. A number of alterations in various signal transduction cascades associated with
metastasis including FAK have been observed following treatment of several cancer cell lines with
fangchinoline as highlighted below.
The MAPK/ERK pathway (also called the Ras-Raf-MEK-ERK pathway) is a FAK downstream
pathway that includes the expression of G protein (RAS) and protein kinases (RAF, MEK, ERK1 and 2).
After the binding of a ligand to the membrane receptor tyrosine kinase, a signal is communicated,
causing the translocation of ERK (MAPK) to the nucleus, where it activates transcription factors that
result in gene expression [76]. In MDA-MB-231 breast cancer cells treated with fangchinoline, it has
been demonstrated that inhibition of cell proliferation was induced by the activation of apoptosis via
the mitochondrial apoptotic pathway, and that decreased levels of phosphorylated Akt were associated
with a decreased effect of fangchinoline [25]. Fangchinoline was also found to decrease PI3-K activation
and expression of its downstream signaling pathways, cyclin D1, and matrix metalloproteinase 2 and
9, in addition to decreasing Akt (phospho-Thr308) expression. It also caused an up-regulation of the
expression of caspase-3 and caspase-8 (a family of endoproteases that initiates the process of apoptosis)
in MG63 and U20S cells [28].
In U87 MG and U118 MG cells, it has been shown that fangchinoline decreases the kinase
activity of Akt and deletes its phosphorylation at Thr308 and Ser473 through suppressing the
Akt-mediated signaling cascades, including Akt/p21, Akt/Bad, and Akt/MMPs [34]. Fangchinoline,
in a dose-dependent manner repressed the phosphorylation of Akt and the expression of MMP-2
and 9 at both the mRNA and protein levels, and caused an increased expression of tissue inhibitor
of metalloproteinase TIMP-1 and -2 mRNAs in AGS cells [33]. In MDA-MB 231 cells, long exposure
times to fangchinoline induced a decrease of the levels of MMP-2 and -9 as well as the expression
of NF-κB protein, while the expression of NF-κB transcription factor inhibitor (IκB) was found to be
increased [56].
In the A549 lung adenocarcinoma cell line, fangchinoline inhibited the phosphorylation of FAK
(Tyr397) and its downstream pathways, the FAK-Akt pathway and FAK-MEK-ERK1/2 [29]. In another
recent study, it was noted that fangchinoline exerted its anticancer effects on human melanoma
(A375 and A875) cells by attenuating the phosphorylation of FAK. It was observed that this alkaloid
suppressed the proliferation of cells and metastasis in vitro via decreasing cyclin D1 and paxillin
expression respectively. Moreover, pre-treatment with pharmacological FAK inhibitor (PF-562271)
significantly abolished the growth inhibitory as well as anti-metastatic effects, thus establishing FAK as
one of the key kinases mediating the observed anti-neoplastic effects of fangchinoline in the melanoma
cells [40]. In hepatocellular carcinoma cell lines, HepG2 and PLC/PRF/5, fangchinoline was found
to dose-dependently induce autophagy instead of apoptotic cell death. Nuclear translocation of
p53 was involved in induction of autophagy by fangchinoline, followed by selective transactivation
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of the autophagy-related gene sestrin 2 and initiation of the autophagic process. Signaling by the
AMP-activated protein kinase was also involved as a downstream target of sestrin 2 and induced
rapamycin (mTOR) independent autophagic cell death in both cell lines. It has been previously
demonstrated that, both at a genetic or protein level, a dysregulation of mTOR and its downstream
targets can contribute to malignant tumorigenesis [57,77].
In T24 and 5637 cells treated with fangchinoline, it has been shown that the level of cleavage of
caspase-3 is increased, in addition to an up-regulation of the LC3-II/LC3-I ratio and down-regulation
of p62 level in a concentration-dependent manner, in addition to the inhibition of mTOR and reduction
of the intracellular ATP levels [32]. Additionally, it was found that treatment of PC3 prostate
cancer cell lines with fangchinoline leads to an increase in protein p27 expression, the inhibition
of cyclin-regulated signaling pathways associated with the arrest of the G1/S phase, and inhibition of
cyclin D and proliferating cell nuclear antigen expression [30]. In K562 cells derived from the blast
crisis of chronic myeloid leukemia, fangchinoline induced cell cycle arrest at the G0/G1 phase through
the up-regulation of cyclin-dependent kinase (CDK)-N1A and MCL-1 mRNA levels, as well as the
down-regulation of cyclin D2 mRNA levels [31]. Fangchinoline, in a dose-dependent manner, arrested
the cell cycle at the G0/G1 phase in SPC-A-1 lung adenocarcinoma cells, which was associated with
a decrease in their proliferation [36]. It has been shown in several studies that the orphan nuclear
receptor subfamily 4 group A member 1 of the nerve growth factor IB (NR4A1) is over-expressed in
human pancreatic cancer, and antagonizing this receptor promotes apoptosis and inhibits pancreatic
tumor cell growth [55]. In human pancreatic cancer cells, fangchinoline inhibited cell proliferation and
induced apoptosis, in part through the NR4A1-dependent pro-apoptotic pathways. It also decreased
the expression of the anti-apoptotic protein, survivin, by inhibiting 1 (Sp1)-mediated transcription
and caused oxidative stress-mediated endoplasmic reticulum (ER) stress in pancreatic cancer cells [55].
In human breast cancer cell lines, MCF-7 and MDA-MB-231, it has been shown that fangchinoline
significantly inhibited the expression of cyclins D1, 3, and E, the kinase activities of CDK2, 4, and 6
(which are over-expressed in breast cancer) and increased the expression of cyclin-dependent kinase
(CDK) inhibitors p21/WAF1, and p27/KIP1 [27,78].
3.5. Effects on Multi-Drug Resistance and Other Parameters
Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer
chemotherapies and other autoimmune diseases. It is mediated by various cellular pathways, some
of which remain to be elucidated [79]. The results of a recent study conducted in vivo in rats, as well
as in vitro, suggest that fangchinoline has a protective effect against the liver toxicity induced by
paracetamol/carbon tetrachloride, and it may be due to the synergistic action of fangchinoline through
free radical scavenging that prevents oxidative stress [80].
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease caused by the oncoprotein
BCR-ABL, which has a main tyrosine kinase activity. So far, the first-line therapy for CML is imatinib
mesylate (IM), which has an inhibitory effect on the tyrosine kinase activity of BCR-ABL. Unfortunately,
in a number of patients, IM has a lower efficiency in the advanced stages of CML due to the apparition
of mutations that amplify the BCR-ABL gene expression and thus the development of IM resistance.
Fangchinoline was found to induce cell cycle and proliferation arrest of the blast crisis, thus by passing
the resistance mechanism, which suggests that fangchinoline may be a potential effective anti-tumor
agent against CML [31].
A particular class of transmembrane glycoproteins (P-glycoprotein; P-gp) functions as
an energy-dependent drug-efflux pump, and thus induces multi-drug resistance to cancer
treatment [81,82]. A recent study was conducted in vitro in MDR1-MDCK II cells, which originate
from transfection of Madin Darby canine kidney MDCK cells with the MDR1 gene that encodes
for the efflux protein, P-gp. It was shown that fangchinoline decreased the efflux of paclitaxel
and inhibited the multi-drug resistance of the drug mediated by P-gp [83,84]. It has also been
reported previously that fangchinoline, along with another alkaloid tetrandrine, can exert a synergistic
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cytotoxic effect in MDR Caco-2 and CEM/ADR5000 cancer cells in conjunction with doxorubicin
treatment. Interestingly, both tetrandrine and fangchinoline augmented the intracellular accumulation
of the fluorescent P-gp substrate rhodamine 123, inhibited its efflux and significantly reduced P-gp
expression in a concentration-dependent manner [85]. The results of another study provided evidence
that fangchinoline can act as a Ca2+ channel blocker, and then mitigate the harmful effects of
cyanide-induced neuronal cell death by inhibiting glutamate release and oxidants generation. It also
interfered with the increase in Ca2+ concentration observed due to the harmful effects of H2O2-induced
neuronal cell death, and inhibited glutamate release as well as the generation of reactive oxygen
species [86]. Overall, the various molecular targets modulated by fangchinoline are briefly summarized
in Table 1.
Table 1. Molecular targets modulated by fangchinoline in in vitro and in vivo models of cancer.
Cancer Types ConcentrationRange Tested Pathways/Molecules Altered References
A549 lung adenocarcinoma 10–40 µM
FAK ↓;
FAK-paxillin/MMP-2&-9 ↓;
FAK-Akt ↓;
FAK-MEK-ERK1&2 ↓
[29]
MG63 and U20S bone cancer 10–30 µM
PI3K ↓;
Cyclin D1 ↓;
MMP2&9 ↓;
Akt ↓;
Caspase3 &8 ↑
[28]
MDA-MB-231 breast cancer 6.25–100 µM
MMP-2&-9 ↓
Expression of NF-κB ↓
Phosphorylated Akt ↓
IκB protein ↑
[25,56,87]
SPC-A-1 lung adenocarcinoma 2.5–10 µM G0/G1 phase Arrest ↓ [36]
T24 and 5637 bladder cancer 2.5–40 µM
Caspase-3 ↓
LC3-II/LC3-I ratio ↑
p62 ↓
mTOR ↓
Intracellular ATP level ↓
[32]
PC3 prostate cancer 10–30 µM
G1/S phase ↓
Cyclin-D ↓
PCNA ↓
p27 expression ↑
[30]
U87MG and U118MG GBM 10–30 µM
Akt/p21 ↓
Akt/BAD ↓
Akt/MMP2&9↓
[34]
HepG2 and PLC/PRF/5 hepatocellular carcinoma 2–10 µM
p53 ↑
Sestrin2 ↑
AMP ↑
[57]
AGS gastric
cancer 0–60 µM
Akt↓
MMP2&9 ↓
TIMP1&2 ↑
[33]
A375 and A875 melanoma 10–20 µM FAK ↓ [40]
MiaPaCa-2 and Panc-1 pancreatic cancer 0–15 µM
NR4A1 ↓
Survivin ↓
Sp-1 ↓
[55]
FAK: Focal adhesion kinase. MMP2&9: Matrix metalloproteinases. Akt: Protein kinase B. MEK: Mitogen-activated
protein kinases. ERK: Extracellular signal-regulated kinases. PI3K: Phosphoinositide 3-kinase. NF-κB: Nuclear
factor kappa-light-chain-enhancer of activated B cells. IκB protein: NF-κB transcription factor inhibitor. LC3:
Microtubule-associated protein 1A/1B-light chain 3. p62: Nucleoporin p62. mTOR: Mechanistic target of rapamycin.
ATP: Adenosine triphosphate. PCNA: Proliferating cell nuclear antigen. p27: Cyclin-dependent kinase inhibitor 1B.
BAD: Bcl-2-associated death promoter. NR4A1: Nuclear receptor subfamily 4 group A member 1 of the nerve growth
factor IB. Sp-1: Specificity protein 1, p53: Phosphoprotein, cellular tumor antigen. AMP: Adenosine monophosphate.
TIMP: Metallopeptidase inhibitor 1. ↑: Upregulation. ↓: Downregulation.
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3.6. In Vivo Effects
In PC-3 tumor-bearing nude mice treated with fangchinoline, an induction of apoptosis was
observed in addition to an inhibition of tumor growth and a decrease in proteasome activities in tumor
xenografts in both a dose- and time-dependent manner [88].
Fangchinoline was also found to exert an antidepressant-like action in mice via acting at multiple
molecular targets [89]. Interestingly, Deng and coworkers reported that fangchinoline significantly
abrogated the tumor growth in breast cancer xenograft mouse model by modulating the expression
of various oncogenic biomarkers including CD117 and Ki-67 [87]. In addition, it has been found that
fangchinoline can effectively attenuate the growth of subcutaneous osteosarcoma tumors in Balb/c
mice through the modulation of activation of PI3K and its associated signal transduction pathways [28].
However, additional preclinical studies are required to validate the potential anti-antiangiogenic and
anti-metastatic effects of fangchinoline in suitable mouse models.
3.7. Effects of the Derivatives of Fangchinoline
In P388/ADR mouse lymphoma cancer cell lines, it has been shown that an addition of a derivative
of fangchinoline to vinblastine significantly enhanced its anticancer potency. This effect was greater in
comparison with verapamil, another cancer drug that acts through the inhibition of calcium channels
and was found to be mediated by increase in the intracellular levels of vinblastine, thereby leading
to its accumulation in P388/ADR cells as well as prolonging the life-span of P388/ADR-bearing
mice [81,82].
4. Conclusions
This mini-review briefly summarizes the pleiotropic anti-cancer properties of fangchinoline.
In vitro and in vivo findings have identified few important molecular and cellular targets, as well as the
mechanisms of action by which the anti-cancer effects (inhibition of tumor cell proliferation, metastasis,
and induction of cell apoptosis and autophagy) of fangchinoline and its few derivatives could be
exerted. Fangchinoline was also observed to have an inhibitory effect on important oncogenic pathways
(FAK, MEK-ERK1/2, NF-κB, PI3K-Akt-mTOR) in diverse tumor cells (Figure 2). Finally, the significant
anti-tumor potential of fangchinoline against tumor cell lines together with the significant efficacy
observed in preclinical models of selected cancers, makes a case for further preclinical as well as clinical
studies of its use as a novel therapeutic agent for the treatment of malignancies.
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